Genetically modified immune cells targeting tumor antigens
Mansour Poorebrahim, Mohammad Foad Abazari, Solmaz Sadeghi, Reza Mahmoudi, Asma Kheirollahi, Hassan Askari, Stina L. Wickström, Vahdat Poortahmasebi, Andreas Lundqvist, Rolf Kiessling, Ángel Cid-Arregui
Abstract
Immunotherapy approaches consisting of genetically modified immune cells have become a promising platform for cancer treatment. Such 'living' therapies targeting tumor antigens have shown success in many cancer patients in the form of durable responses in a growing number of clinical studies. Besides, a large number of ongoing studies have been designed to introduce reliable methods for identification of tumor antigens. In addition, technical and biotechnological developments are being applied to the generation and expansion of genetically modified immune cells. In this review, we summarize and discuss the latest progress and current challenges in the tumor antigen landscape and in the generation of genetically modified immune cells in view of their clinical efficacy, either as monotherapy or combinational therapy.